Abstract
A new study uses genome-wide SNP genotypes to identify a subset of children undergoing therapy for acute lymphoblastic leukemia that are at increased risk for relapse. Borrowing from the classical approach of admixture mapping, the work shows how genome-wide assessment of genetic ancestry can be used as a biomarker for disease outcome.
Original language | English (US) |
---|---|
Pages (from-to) | 178-179 |
Number of pages | 2 |
Journal | Nature genetics |
Volume | 43 |
Issue number | 3 |
DOIs | |
State | Published - Mar 2011 |
Externally published | Yes |
ASJC Scopus subject areas
- Genetics